	US 12,144,818 B2
	Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
Elisabeth Rouits, Crissier (CH); and Nigel Mccracken, Begnins (CH)
Assigned to DEBIOPHARM INTERNATIONAL, S.A., Lausanne (CH)
Appl. No. 17/059,698
Filed by DEBIOPHARM INTERNATIONAL, S.A., Lausanne (CH)
PCT Filed May 29, 2019, PCT No. PCT/IB2019/054457 § 371(c)(1), (2) Date Nov. 30, 2020, PCT Pub. No. WO2019/229677, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/677,782, filed on May 30, 2018.
Prior Publication US 2021/0196835 A1, Jul. 1, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 31/573 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01)

CPC A61K 31/573 (2013.01) [A61K 38/193 (2013.01); A61K 47/68033 (2023.08); A61K 47/6867 (2017.08); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01)]

20 Claims

1. A method for treating a cancer in a human patient comprising administering to the patient a pharmaceutical composition comprising an anti-CD37 immunoconjugate once a week in a three-week cycle, wherein:

a) 0.4 mg/kg of the immunoconjugate are administered in the first week, 0.2 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

b) 0.2 mg/kg of the immunoconjugate are administered in the first week, 0.2 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

c) 0.3 mg/kg of the immunoconjugate are administered in the first week, 0.3 mg/kg are administered in the second week, and 0.3 mg/kg are administered in the third week;

d) 0.3 mg/kg of the immunoconjugate are administered in the first week, 0.3 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

e) 0.3 mg/kg of the immunoconjugate are administered in the first week, 0.2 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

f) 0.4 mg/kg of the immunoconjugate are administered in the first week, 0.3 mg/kg are administered in the second week, and 0.3 mg/kg are administered in the third week;

g) 0.4 mg/kg of the immunoconjugate are administered in the first week, 0.3 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

h) 0.5 mg/kg of the immunoconjugate are administered in the first week, 0.3 mg/kg is administered in the second week, and 0.2 mg/kg are administered in the third week;

i) 0.5 mg/kg of the immunoconjugate are administered in the first week, 0.2 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week; or

j) 0.6 mg/kg of the immunoconjugate are administered in the first week, 0.2 mg/kg are administered in the second week, and 0.2 mg/kg are administered in the third week;

wherein the immunoconjugate comprises (i) an antibody or antigen-binding fragment thereof comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:2, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:3, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:4, a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:5, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:6, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:7 and (ii) a maytansinoid.